President Donald Trump and other administration officials are claiming credit for a recent drop in prescription drug prices, citing deals they’ve struck with drugmakers and the launch of the online direct-to-consumer platform TrumpRx. But experts are skeptical those measures have had much impact on prices overall, and they say other factors likely explain most of the decline.
Issues: prescription drugs
The Shaky Assumptions Behind Trump’s Over $500 Billion in Projected Drug Savings
RFK Jr.’s Muddled Claims on Drug Approval Speed
The Food and Drug Administration in recent months has approved a small number of drugs quite quickly under a new expedited review program. But Health and Human Services Secretary Robert F. Kennedy Jr. has overstated the impact of the program by making misleading comparisons to the pace of drug approvals in the past.
Trump Misleads on Drug Pricing Deals
President Donald Trump has said that Americans are now paying or will pay “the lowest price anywhere in the world for drugs,” thanks to the administration’s negotiations with pharmaceutical companies. The administration has announced discounted cash prices for a small number of brand-name drugs. There isn’t evidence Trump’s deals so far have led to broad decreases in drug prices, nor is it certain they will in the future.








